Form 4: Amicus Therapeutics Director Glenn Sblendorio Exercises Stock Options
SEC Form 4 Filing
Director Glenn Sblendorio exercised stock options to acquire 15,000 shares of Amicus Therapeutics common stock at $2.8 per share on March 7, 2024.
Summary
- On March 7, 2024, Glenn Sblendorio, a director of Amicus Therapeutics, Inc., exercised stock options to acquire 15,000 shares of common stock.
- The exercise price was $2.8 per share.
- Following the transaction, Sblendorio directly owns 83,596 shares of Amicus Therapeutics common stock.
- The stock options were fully vested and exercisable as of the transaction date.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: Glenn Sblendorio exercised stock options. |
| 03/11/2024 | Date of signature on the Form 4 filing. |
| 06/12/2024 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.